Antares Pharma, Inc. (NASDAQ:ATRS) Director Thomas J. Garrity Sells 70,000 Shares of Stock


Share on StockTwits

Antares Pharma, Inc. (NASDAQ:ATRS) Director Thomas J. Garrity sold 70,000 shares of the firm’s stock in a transaction dated Monday, January 11th. The stock was sold at an average price of $4.06, for a total value of $284,200.00. Following the completion of the transaction, the director now owns 244,406 shares of the company’s stock, valued at approximately $992,288.36. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of ATRS opened at $4.18 on Thursday. The company has a market cap of $696.69 million, a PE ratio of 69.68 and a beta of 1.44. The company has a current ratio of 2.47, a quick ratio of 2.08 and a debt-to-equity ratio of 0.53. The stock has a 50-day moving average price of $3.67 and a 200-day moving average price of $3.05. Antares Pharma, Inc. has a 12-month low of $1.60 and a 12-month high of $4.58.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, November 10th. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.01. The firm had revenue of $40.00 million during the quarter, compared to the consensus estimate of $36.09 million. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. As a group, analysts predict that Antares Pharma, Inc. will post 0.06 earnings per share for the current year.

Several research analysts have commented on ATRS shares. Zacks Investment Research downgraded Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, January 4th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, December 17th. TheStreet upgraded Antares Pharma from a “c” rating to a “b-” rating in a research note on Wednesday, November 25th. Finally, Raymond James restated a “buy” rating on shares of Antares Pharma in a research note on Thursday, October 1st. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $5.15.

Institutional investors and hedge funds have recently modified their holdings of the company. Boothbay Fund Management LLC lifted its position in Antares Pharma by 93.4% in the 3rd quarter. Boothbay Fund Management LLC now owns 21,746 shares of the specialty pharmaceutical company’s stock worth $59,000 after buying an additional 10,504 shares during the last quarter. Jane Street Group LLC bought a new stake in Antares Pharma in the 2nd quarter worth approximately $62,000. LVW Advisors LLC bought a new stake in Antares Pharma in the 3rd quarter worth approximately $68,000. Aperio Group LLC lifted its position in Antares Pharma by 28.2% in the 3rd quarter. Aperio Group LLC now owns 33,276 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 7,329 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in Antares Pharma by 445.3% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 38,750 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 31,644 shares during the last quarter. Hedge funds and other institutional investors own 39.92% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Key terms to understand channel trading

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.